Department of Psychosomatic Medicine, University Hospital Basel, Basel, Switzerland.
Faculty of Medicine, University of Basel, Basel, Switzerland.
Epidemiol Psychiatr Sci. 2022 Mar 25;31:e16. doi: 10.1017/S2045796021000676.
Several diseases are linked to increased risk of Coronavirus disease 19 (COVID-19). Our aim was to investigate whether depressive and anxiety symptoms predict subsequent risk of COVID-19, as has been shown for other respiratory infections.
We based our analysis on UK Biobank participants providing prospective data to estimate temporal association between depressive and anxiety symptoms and COVID-19. We estimated whether the magnitude of these symptoms predicts subsequent diagnosis of COVID-19 in this sample. Further, we evaluated whether depressive and anxiety symptoms predicted (i) being tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and (ii) COVID-19 in those tested.
Based on data from N = 135 102 participants, depressive symptoms (odds ratio (OR) = 1.052; 95% confidence interval (CI) 1.017-1.086; absolute case risk: (moderately) severe depression: 493 per 100 000 v. minimal depression: 231 per 100 000) but not anxiety (OR = 1.009; 95% CI 0.97-1.047) predicted COVID-19. While depressive symptoms but not anxiety predicted (i) being tested for SARS-CoV-2 (OR = 1.039; 95% CI 1.029-1.05 and OR = 0.99; 95% CI 0.978-1.002), (ii) neither predicted COVID-19 in those tested (OR = 1.015; 95% CI 0.981-1.05 and OR = 1.021; 95% CI 0.981-1.061). Results remained stable after adjusting for sociodemographic characteristics, multimorbidity and behavioural factors.
Depressive symptoms were associated with a higher risk of COVID-19 diagnosis, irrespective of multimorbidities. Potential underlying mechanisms to be elucidated include risk behaviour, symptom perception, healthcare use, testing likelihood, viral exposure, immune function and disease progress. Our findings highlight the relevance of mental processes in the context of COVID-19.
一些疾病与 2019 年冠状病毒病(COVID-19)的风险增加有关。我们的目的是研究抑郁和焦虑症状是否会预测 COVID-19 的后续风险,因为这已经在其他呼吸道感染中得到证实。
我们基于英国生物库参与者提供的前瞻性数据来估计抑郁和焦虑症状与 COVID-19 之间的时间关联。我们估计在该样本中这些症状的严重程度是否预测随后 COVID-19 的诊断。此外,我们评估了抑郁和焦虑症状是否预测了以下情况:(i)接受严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)检测;(ii)在接受检测的人群中 COVID-19 的发生。
基于来自 N=135102 名参与者的数据,抑郁症状(比值比(OR)=1.052;95%置信区间(CI)1.017-1.086;绝对病例风险:(中度)重度抑郁症:每 100000 人中有 493 例,而轻度抑郁症:每 100000 人中有 231 例)但不是焦虑(OR=1.009;95%CI 0.97-1.047)预测了 COVID-19。虽然抑郁症状但不是焦虑症状预测了(i)接受 SARS-CoV-2 检测(OR=1.039;95%CI 1.029-1.05 和 OR=0.99;95%CI 0.978-1.002),(ii)在接受检测的人群中均未预测 COVID-19(OR=1.015;95%CI 0.981-1.05 和 OR=1.021;95%CI 0.981-1.061)。调整社会人口统计学特征、多种合并症和行为因素后,结果仍然稳定。
抑郁症状与 COVID-19 诊断的风险增加有关,无论是否存在多种合并症。需要阐明的潜在机制包括风险行为、症状感知、医疗保健使用、检测可能性、病毒暴露、免疫功能和疾病进展。我们的研究结果突出了心理过程在 COVID-19 背景下的重要性。